Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

KIF20A-derived peptide plus gemcitabine evaluated in pancreatic cancer trial

Jan. 24, 2014

California Stem Cell submits phase II trial protocol to FDA for Ovapuldencel-T

Jan. 24, 2014

Advaxis and Biocon to collaborate on novel cancer immunotherapy

Jan. 23, 2014

OMP-59R5 proves active against metastatic pancreatic cancer

Jan. 23, 2014

Simtuzumab well tolerated in phase I and II trials

Jan. 21, 2014

Takeda obtains approval of Adcetris for treatment of malignant lymphoma in Japan

Jan. 17, 2014

Immunomedics begins phase III trial of yttrium Y 90 clivatuzumab tetraxetan

Jan. 16, 2014

Synthon Biopharmaceuticals prepares for phase I study of SYD-985

Jan. 16, 2014

Merck & Co. begins rolling submission of BLA for MK-3475

Jan. 14, 2014

Monoclonal antibody Hu3F8 receives FDA orphan drug status for osteosarcoma

Jan. 14, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...